TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MSTR
Strategy
-- 304.000 AAPL
Apple
-- 218.270 
NEWS
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NeuroSense Therapeutics (NASDAQ: NRSN) has initiated the regulatory process for early commercialization approval of PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This decision follows positive Phase 2b trial results showing PrimeC reduces ALS disease progression by 36% (p=0.009) and improves survival rates by 43% compared to placebo.
The company plans to seek approval in additional countries based on these promising results. NeuroSense CEO, Alon Ben-Noon, expressed confidence in PrimeC's potential to address urgent unmet needs in ALS treatment and the company's commitment to expediting access to this therapy.
The company plans to seek approval in additional countries based on these promising results. NeuroSense CEO, Alon Ben-Noon, expressed confidence in PrimeC's potential to address urgent unmet needs in ALS treatment and the company's commitment to expediting access to this therapy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment